LAB/IN VITRO RESEARCH e-ISSN 1643-3750 © Med Sci Monit, 2018; 24: 1517-1523 DOI: 10.12659/MSM.908060
Circulating miR-23b as a Novel Biomarker for Early Risk Stratification After ST-Elevation Myocardial Infarction
Received: 2017.11.15 Accepted: 2017.11.21 Published: 2018.03.14
Authors’ Contribution: Study Design A Data Collection B Analysis C Statistical Data Interpretation D Manuscript Preparation E Literature Search F Funds Collection G
B 1 C 2 ADEG 3
Jungang Zhang Yaxing Li Qingzhen Zhao
1 Institute of Health Toxicology, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, P.R. China 2 Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, P.R. China 3 Department of Cardiology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, P.R. China
Corresponding Author: Qingzhen Zhao, e-mail:
[email protected] Source of support: None
Background:
Material/Methods:
Results:
Conclusions:
MeSH Keywords:
Full-text PDF:
miR-23b overexpression can promote cardiomyocyte apoptosis and reduce cell growth under hypoxic conditions, suggesting that miR-23b acts as a biomarker for ST-elevation myocardial infarction (STEMI). The aim of this study was to investigate the effect of miR-23b on STEMI patients. We enrolled 80 eligible patients with STEMI and 60 control subjects. Blood samples were obtained at 6 h, 12 h, 24 h, 48 h, 3 days, and 7 days after the onset of symptoms. Another blood sample was collected before and after percutaneous coronary intervention (PCI). The samples were used for real-time quantitative PCR analysis. A Siemens Immulite2000 detector (Germany) was used for cTnI detection, and the serum CK-MB content was detected by electrochemical luminescence method. The expression level of miR-23b was increased in patients with STEMI (P0.05). The level of miR-23b in STEMI patients after PCI was lower (P
